Table 1.

Characteristics of articles in the meta-analysis on chemotherapy and luminal A breast cancer

Author, year	Country, follow-up (median)	Study design	Sample size	Chemotherapy regimen	Outcome indicators
Uchida et al.2013 [10]	Japan, 3–113 (40) months	Retrospective study	140	FEC × 4/FEC × 4-docetaxel × 4 or paclitaxel × 4	RFS, OS
Kwak et al. 2015 [16]	South Korea, 28–116 (61) months	Retrospective study	879	No detail description	DFS, OS
Han et al. 2015 [17]	China, 60–89 (67) months	Retrospective cohort study	1580	AC × 4/AC × 6	DFS, OS
Nielsen et al. 2016 [18]	UK, 10 years (median)	Clinical trial	1072 (luminal A n = 165)	C × 12/CMF × 12	DFS, OS (not provided)
Alramadhan et al. 2016 [19]	South Korea, 51.3 ± 18.9(median)	Retrospective study	406	AC × 4/FAC × 4	DFS, OS (not provided)
Herr et al. 2019 [20]	Multicenter, -	Retrospective multicenter Study	1376	A/AT	RFS, OS

F fluorouracil, E epirubicin, C cyclophosphamide, A anthracycline, M methotrexate; T Taxane, RFS relapse-free survival, OS overall survival, DFS disease-free survival